The VA National Acquisition Center intends to issue an unrestricted RFP for Glipizide Tablets to supply VA (including CMOPs and Option 2 State Veterans Homes), DoD, BOP, IHS, and FHCC. VA will award one contract to a responsible offeror able to provide an uninterrupted source of supply, with a one-year base period plus four pre-priced one-year option periods, distributed through the VA and DoD Pharmaceutical Prime Vendor Programs. The product requires unit-of-use packaging, unique NDC labeling, safety-cap/convertible-cap bottles, and specified bottle dimensions, with estimated annual usage quantities provided for multiple 5 mg and 10 mg tablet package sizes. The solicitation will be issued electronically in commercial item format under FAR Part 12 on or about July 27, 2026, and will be available for download at SAM.gov with no paper copies. Interested offerors must state the exact label name and unique NDC and should continuously monitor SAM.gov for amendments and changes.

The VA National Acquisition Center intends to award a single contract for Glipizide Tablets (5mg and 10mg) in various unit-of-use bottle sizes, with estimated annual bottle quantities listed for each item. This unrestricted procurement is open to all responsible sources and covers a one-year base period plus four pre-priced one-year option periods. The contract will supply the Department of Veterans Affairs (including CMOPs and State Veterans Homes), Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center, with distribution through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide the drug under their own unique NDC label and meet specific packaging requirements, including safety caps, cylindrical bottle dimensions, and label sizing. Interested parties should monitor SAM.gov for